Signs and Symptoms with MCC DRG Reimbursement Guide

DRG 947 encompasses inpatient stays for nonspecific signs and symptoms accompanied by a Major Complication or Comorbidity, covering resource use for diagnostic workup and management. This classification influences inpatient reimbursement because the Major Complication or Comorbidity status increases the payment weighting under the Medicare inpatient prospective payment system.

DRG 947 Overview

DRG 947 covers hospital admissions primarily coded for general signs and symptoms when a Major Complication or Comorbidity is present, rather than a definitive principal diagnosis. This category captures encounters where diagnostic evaluation, monitoring, and short-term treatment for nonspecific clinical presentations drive resource use. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates relative weight and reimbursement compared with cases without such comorbidity, reflecting higher expected resource intensity. Accurate clinical documentation and coding of the contributing signs, symptoms, and Major Complication or Comorbidity determine assignment to this Diagnosis-Related Group.

Acute diagnostic and management trials for undifferentiated signs and symptoms: randomized or prospective cohort studies testing protocols for rapid diagnosis and early management in hospitalized adults presenting with nonspecific signs (eg, syncope, altered mental status, chest pain without clear ischemia, dyspnea) who have one or more major complications or comorbidities. These studies evaluate decision pathways, use of observation units, algorithmized imaging or biomarker panels, and time-to-diagnosis metrics to reduce delays and unnecessary resource use. Findings are directly relevant to inpatient teams and payers because improved early diagnostic efficiency can shorten length of stay, reduce use of costly tests, and lower complication rates among high-risk patients classified under this DRG.
Comparative effectiveness studies of acute care strategies across comorbidity strata: pragmatic trials or large observational comparative-effectiveness research comparing different inpatient management approaches (eg, conservative vs. protocolized aggressive workup, varying levels of monitoring or telemetry, or differing antibiotic stewardship and supportive care bundles) in patients admitted for signs and symptoms who also have major comorbid conditions. These studies stratify by age, frailty, and specific MCC profiles to identify which approaches yield better clinical outcomes, readmission rates, or resource utilization. Results inform clinicians and payers about which care pathways are most cost-effective and clinically appropriate for diverse high-risk subgroups within DRG 947.
Post-discharge outcomes and transitional care research: longitudinal cohort studies and intervention trials evaluating discharge planning, early post-discharge follow-up, home health integration, and remote monitoring for patients discharged after hospitalization for signs and symptoms with major complications. Research measures rates of readmission, functional recovery, patient-centered outcomes, and downstream costs, particularly in populations with multimorbidity and complex social needs. This area is crucial for payers and health systems seeking to reduce rehospitalization, optimize post-acute resource allocation, and improve long-term outcomes for patients in this DRG.

Acute diagnostic and management trials for undifferentiated signs and symptoms: randomized or prospective cohort studies testing protocols for rapid diagnosis and early management in hospitalized adults presenting with nonspecific signs (eg, syncope, altered mental status, chest pain without clear ischemia, dyspnea) who have one or more major complications or comorbidities. These studies evaluate decision pathways, use of observation units, algorithmized imaging or biomarker panels, and time-to-diagnosis metrics to reduce delays and unnecessary resource use. Findings are directly relevant to inpatient teams and payers because improved early diagnostic efficiency can shorten length of stay, reduce use of costly tests, and lower complication rates among high-risk patients classified under this DRG.
Comparative effectiveness studies of acute care strategies across comorbidity strata: pragmatic trials or large observational comparative-effectiveness research comparing different inpatient management approaches (eg, conservative vs. protocolized aggressive workup, varying levels of monitoring or telemetry, or differing antibiotic stewardship and supportive care bundles) in patients admitted for signs and symptoms who also have major comorbid conditions. These studies stratify by age, frailty, and specific MCC profiles to identify which approaches yield better clinical outcomes, readmission rates, or resource utilization. Results inform clinicians and payers about which care pathways are most cost-effective and clinically appropriate for diverse high-risk subgroups within DRG 947.
Post-discharge outcomes and transitional care research: longitudinal cohort studies and intervention trials evaluating discharge planning, early post-discharge follow-up, home health integration, and remote monitoring for patients discharged after hospitalization for signs and symptoms with major complications. Research measures rates of readmission, functional recovery, patient-centered outcomes, and downstream costs, particularly in populations with multimorbidity and complex social needs. This area is crucial for payers and health systems seeking to reduce rehospitalization, optimize post-acute resource allocation, and improve long-term outcomes for patients in this DRG.

OpenPayer

Summary & Overview

Signs and Symptoms with Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 947 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes